ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0417

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

Eduardo Martin-Nares1, Janette Furuzawa-Carballeda1, Ángel Alexis Priego-Ranero1, Isela Chan-Campos1, Gladys Sulikey Herrera-Noguera1, Fidel López-Verdugo1 and Gabriela Hernandez-Molina1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Fibrosing syndromes, IgG4 Related Disease, Miscellaneous Rheumatic and Inflammatory Diseases, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are also differences in the immunophenotype of each phenotype is unknown. Our aim was to characterize the immunophenotype of IgG4-RD patients according to their clinical phenotype.

Methods: We included consecutive patients with a diagnosis of IgG4-RD according to the Comprehensive Diagnostic Criteria for IgG4-RD who attended our Institution from Aug 2018 to Nov 2019. Healthy subjects were included as controls. We obtained peripheral blood for isolation of peripheral mononuclear cells and through negative selection, CD4+ memory T cells were obtained. We determined the percentage of the following cell subsets by flow cytometry:

  • Th2 (CD4+/CD45RO+/CD14-/IL-4+; CD4+/CD45RO+/CD14-/IL-13+, CD4+/CD45RO+/CD14-/IL-5+);
  • CD4+IL-21 T cells (CD4+/CD45RO+/CD14-/IL-21+);
  • CD4+ cytotoxic T cells (CTLs) (CD4+/CD45RO+/SLAMF7+/IL-1β+/TGF-β1+);
  • Th9 (CD3+/CD4+/ CD45RO+/IL-9);
  • T follicular helper cells (Tfh) (CD4+/CD45RO+/CCR7-/ICOS+/CCCR5+/Bcl6+);
  • Tfh1 (CD4+/CD45RO+/CCR7-/ICOS+/CCCR5+/Bcl6+/IFN-γ+);
  • Tfh2 (CD4+/CD45RO+/CCR7-/ICOS+/CCCR5+/Bcl6+/IL-4+);
  • Tfh17 (CD4+/CD45RO+/CCR7-/ICOS+/CCCR5+/Bcl6+/IL-17+);
  • Tfr (CD4+/CD45RO+/CCR7-/ICOS+/CCCR5+/Bcl6+/Foxp3+);
  • Tregs (CD4+/CD25hi/CD127-/Foxp3+);
  • Tr1 (CD4+/CD25low/Foxp3-/IL-10+);
  • Th3 (CD4+/CD25-/Foxp3-/TGF-β1+);
  • Bregs (CD19+/CD24hi/CD38hi/IL-10+);
  • Plasmocitoid dendritic cells (pDC) (CD86+/CD163hi/IL-10+);
  • M1 macrophages (CD86+/CD127+/TNF-α+);
  • M2 macrophages (CD163+/CD14+/TGF-β1+/IL-33+).

Results: We recruited 43 patients with a mean age of 52.3±16.4 years, 48.8% were male. Twelve controls were included. Eight (18.6%) patients belong to the pancreato-hepatobiliary, 7 (16.3%) to the retroperitoneal-aorta, 16 (37.2%) to the head and neck limited and 12 (27.9%) to the Mikulicz/Systemic phenotypes. Twenty two (51.2%) had active disease. The percentages of all cell subsets were statistically higher in patients vs controls, with the exception of Tr1 cells. The percentages of the following cell subsets were different among clinical phenotypes: Th2 (CD4+/IL-4+) (p=0.029), Th2 (CD4+/IL-5+) (p=0.047), CD4+ CTLs, (p=< 0.001), Tfh17 (p=0.005), Tregs FOXP3+ (p=0.008), Th3 (p=0.02), Bregs (p=0.005) and pDC IL-10 (p=0.016). In a sensitive analysis including only the 22 patients with active disease, the same cell subsets remained significant and we also observed differences in Tfh1 (p=0.03), Tfh2 (p=0.009), Tr1 (p=0.034), and M1 macrophages (p=0.03). Patients with active IgG4-RD had higher proportions of Tfh (< 0.001), Tfh17 (p< 0.001), Tr1 (p=0.001), Th3 (p=0.01), pDC IL-10 (0.005) and M1 macrophages (p=0.017). There were no differences according to the presence of atopy or immunosuppressive treatment at recruitment.

Conclusion: Our study showed that the clinical heterogeneity of IgG4-RD might be driven by the participation of different immune cell subsets.


Disclosure: E. Martin-Nares, None; J. Furuzawa-Carballeda, None; �. Priego-Ranero, None; I. Chan-Campos, None; G. Herrera-Noguera, None; F. López-Verdugo, None; G. Hernandez-Molina, None.

To cite this abstract in AMA style:

Martin-Nares E, Furuzawa-Carballeda J, Priego-Ranero �, Chan-Campos I, Herrera-Noguera G, López-Verdugo F, Hernandez-Molina G. Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/different-immunophenotypes-characterized-igg4-related-disease-clinical-phenotypes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-immunophenotypes-characterized-igg4-related-disease-clinical-phenotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology